WallStreetZenWallStreetZen

NASDAQ: KYTX
Kyverna Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Kyverna Therapeutics revenue was $0.00 for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, KYTX annual revenue was $0.0, with N/A growth year-over-year.

KYTX revenue history

Current Revenue
$0.0
Current Earnings
-$158.7M
Current Profit Margin
0%

Be the first to know when KYTX announces revenue.

KYTX Revenue History By Year

KYTX Yearly RevenueKYTX RevenueKYTX ChangeKYTX Revenue Growth
2024-12-31$0.00N/AN/A
2023-12-31$0.00-$7.03M-100.00%
2022-12-31$7.03M$1.37M+24.20%
2021-12-31$5.66MN/AN/A

1 of 1

Kyverna Therapeutics Revenue FAQ

What was KYTX's revenue last quarter?

On Invalid Date, Kyverna Therapeutics (NASDAQ: KYTX) reported Q2 2025 revenue of $0.00 up N/A year over year. In the same quarter last year, Kyverna Therapeutics's revenue was $0.00.

What was Kyverna Therapeutics's revenue in 2024?

Kyverna Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.

How much does Kyverna Therapeutics make in a day?

Based on Kyverna Therapeutics annual revenue for the past three years, KYTX makes an average of $6,415.53 per day.

What was Kyverna Therapeutics's annual revenue growth in the past year?

As of Q3 2025, Kyverna Therapeutics's revenue has grown null year over year. Kyverna Therapeutics's revenue in the past year totaled $0.00.

How much does Kyverna Therapeutics make in a year?

Kyverna Therapeutics's revenue by year for the past three years is:
  • Kyverna Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.
  • Kyverna Therapeutics's annual revenue for Dec 31, 2023 was $0.00, a 100% decrease from 2022.
  • Kyverna Therapeutics's annual revenue for 2022 was $7.03 million, a 24.2% increase from 2021.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.